[Pubmed] Telitacicept in combination with B-cell depletion therapy in MuSK antibody-positive myasthenia gravis: a case r
Posté : 03 déc. 2024 12:00
Front Immunol. 2024 Nov 18;15:1456822. doi: 10.3389/fimmu.2024.1456822. eCollection 2024.
ABSTRACT
Muscle-specific kinase (MuSK) myasthenia gravis (MG) is relatively rare and has a higher incidence of myasthenic crisis compared with other subtypes. However, there is still a lack of effective treatment for refractory MuSK MG. We report the case of a 70-year-old female MuSK MG patient with recurrent fluctuations who stabilized on telitacicept in combination with anti-CD20 B-cell depletion therapy. This combination regimen deserves further investigation. Furthermore, we summarized the treatment protocols of 14 previously reported cases of MuSK MG.
PMID:39624088 | PMC:PMC11609065 | DOI:10.3389/fimmu.2024.1456822
Source: https://pubmed.ncbi.nlm.nih.gov/3962408 ... t9+e462414